Alkemi

Stop making payers do homework. That’s it. That’s the post. Actually, no. We have more. Too many value stories ask the payer to connect the dots: • Here’s the burden. • Here’s the unmet need. • Here’s the clinical evidence, the economic model, the 47 supporting slides. Now please arrive at the conclusion we wanted. Good luck. That’s not very helpful, or persuasive. Really, it's just assigning homework to someone who already has a full-time job. A strong value story organizes the evidence into a decision. Clear problem. Clear consequence. Clear value. Clear reason to act. That’s what we’ll be talking about at #ISPORAnnual. If you’re in Philly and want to make your value story easier to say yes to, come meet Alkemi. Schedule time: → https://lnkd.in/eS3pJSXg

Philadelphia. ISPOR. Alkemi. Basically, the perfect setup for us to run up the steps and start yelling about impact. Betsy J. Lahue and the Alkemi team are heading to #ISPORAnnual in Philadelphia. If you see us in the halls, feel free to raise your coffee cup and shout: “ADRIANNNNNN!” Or better yet… grab us before we start shadowboxing another 300-page PDF. We’ll be talking about: → Evidence that actually gets used → Value stories that survive payer conversations → Global-local tools that don’t immediately disappear into SharePoint → How to turn HEOR work into decisions, not decorative appendices Because at some point, “comprehensive” became a very expensive way to say “no one knows what to do with this.” Schedule time with us at ISPOR → https://lnkd.in/eS3pJSXg

Evidence deserves better than being buried in an appendix. There. We said it. Too much great HEOR work gets treated like a supporting character in someone else’s strategy deck. The model is strong and the data useful. The insights are valuable. And somehow the final output still makes everyone ask: “So… what do we do with this?” That question should not come at the end. It should come at the beginning. At Alkemi, we believe evidence should be built backward from the decision it needs to shape. Not backward from the table of contents, or the old template. Backward from impact. If you’re at #ISPORAnnual and want to talk about making evidence more useful, more actionable, and less likely to die quietly on page 82, come meet us in Philly. Schedule time with Alkemi → https://lnkd.in/eS3pJSXg

We’re going to ISPOR. Please hide your bloated decks accordingly. At Alkemi, we like evidence. We like rigor. We even like a good framework. What we do not like is pretending that a deliverable created, circulated, and immediately buried in SharePoint counts as impact. It doesn’t. Impact is when the work changes the conversation. When the value story gets clearer. When the evidence helps someone make a better decision. When local teams actually use the thing global sent them. Radical stuff, we know. That’s what we’re bringing to Philadelphia. • Useful evidence. • Sharper strategy. • Fewer sacred PDFs. Come meet the Alkemi team at #ISPORAnnual. Schedule time with us → https://lnkd.in/eS3pJSXg

The 300-page value dossier had a good run. It looked impressive. It made the team feel prepared, gave global something to distribute, and gave local something to ignore. And then reality happened. Someone opened it. Searched for 3 slides. Copied a paragraph into another deck. And moved on with their life. That’s not a collaboration model. That’s a document graveyard with version control. At #ISPORAnnual Philly, we’re interested in a different question: What if the problem isn’t the evidence? What if the problem is the format? Because the best value story in the world won’t matter if it’s buried on page 147. Global teams don’t need to build bigger dossiers. Local teams don’t need more “tools.” Payers definitely don’t need another recycled value message. They need evidence translated into decisions, objections, conversations, and action. That’s the conversation we’re bringing to #ISPORAnnual Philadelphia. The GVD isn’t sacred. The value story is. Interested in our take and how it can make yours better? Click to schedule time with us - https://lnkd.in/eS3pJSXg

We’re excited to welcome Praburaman Mohan to the Alkemi team as an intern. We’re also pleased to continue our partnership with the Geisel School of Medicine at Dartmouth, which started six years ago. It remains a privilege to serve as a preceptor site and support students as they apply their training in a real-world setting. Raman brings a public health lens, intellectual curiosity, and a thoughtful approach to the work, and we’re glad to have him with us.

Alkemi CEO Betsy J. Lahue sharing her experience so it doesn't have to be yours!

The teams that struggle most with access are often the most excited by their own data. They focus on: - the endpoint they like - the MOA they find compelling - the mode of administration that feels more convenient - the cost saving that looks strong in a model But they do not stop to ask: - does this matter to a payer? - does this matter to a provider? - does this change behavior? - does this create problems/costs/friction somewhere else? Because value is not universal. A novel MOA may mean nothing to coverage. A simpler mode of administration may hurt practice economics. A cost saving for one part of the system may reduce income for another. That is how good evidence becomes weak strategy. The issue is not whether the data is strong. It is whether the data is relevant to the people who decide. --- Alkemi helps teams test evidence against real decisions. We work upstream to test whether a claim will matter to payers, providers, and other stakeholders before it becomes the value story or evidence plan. So you can generate evidence that sounds good internally AND holds up externally.